Plasma Coagulation Factor Levels in Venous Thrombosis

Seminars in Hematology

Volumn 44, Issue 2, 2007, Pages 77-84

  Nossent, A Yaël ^a   Eikenboom, Jeroen C J ^a   Bertina, Rogier M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRIN; FIBRINOGEN; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; VON WILLEBRAND FACTOR;

ARTICLE; DNA POLYMORPHISM; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM; VEIN THROMBOSIS;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; HUMANS; RISK FACTORS; VENOUS THROMBOSIS;

EID: 34047266428     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.01.006     Document Type: Article

References (99)

1. Anderson Jr. F.A., Wheeler H.B., Goldberg R.J., Hosmer D.W., Patwardhan N.A., Jovanovic B., et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151 (1991) 933-938
2. Carter C.J. The natural history and epidemiology of venous thrombosis. Prog Cardiovasc Dis 36 (1994) 423-438
3. Brandjes D.P., Büller H.R., Heijboer H., Huisman M.V., de Rijk M., Jagt H., et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 349 (1997) 759-762
4. Rosendaal F.R. Venous thrombosis: A multicausal disease. Lancet 353 (1999) 1167-1173
5. Koster T., Rosendaal F.R., Reitsma P.H., van der Velden P.A., Briët E., and Vandenbroucke J.P. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms-The Leiden Thrombophilia Study (LETS). Thromb Haemost 71 (1994) 719-722
6. van Hylckama Vlieg A., and Rosendaal F.R. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost 1 (2003) 2677-2678
7. Austin H., Hooper W.C., Lally C., Dilley A., Ellingsen D., Wideman C., et al. Venous thrombosis in relation to fibrinogen and factor VII genes among African-Americans. J Clin Epidemiol 53 (2000) 997-1001
8. Tsai A.W., Cushman M., Rosamond W.D., Heckbert S.R., Tracy R.P., Aleksic N., et al. Coagulation factors, inflammation markers, and venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Med 113 (2002) 636-642
9. de Maat M.P., and Verschuur M. Fibrinogen heterogeneity: Inherited and noninherited. Curr Opin Hematol 12 (2005) 377-383
10. Kamphuisen P.W., Eikenboom H.C.J., Vos H.L., Pablo R., Sturk A., Bertina R.M., et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 81 (1999) 680-683
11. Renner W., Cichocki L., Forjanics A., Koppel H., Gasser R., and Pilger E. G-455A polymorphism of the fibrinogen beta gene and deep vein thrombosis. Eur J Clin Invest 32 (2002) 755-758
12. Uitte de Willige S., De Visser M.C.H., Houwing-Duistermaat J.J., Rosendaal F.R., Vos H.L., and Bertina R.M. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood 106 (2005) 4176-4183
13. Bertina R.M., van Tilburg N.H., de Fouw N.J., and Haverkate F. Thrombin, a link between coagulation activation and fibrinolysis. Ann N Y Acad Sci 667 (1992) 239-248
14. Lane D.A., Philippou H., and Huntington J.A. Directing thrombin. Blood 106 (2005) 2605-2612
15. Poort S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
16. Legnani C., Cosmi B., Valdre L., Boggian O., Bernardi F., Coccheri S., et al. Venous thromboembolism, oral contraceptives and high prothrombin levels. J Thromb Haemost 1 (2003) 112-117
17. Folsom A.R., Cushman M., Tsai M.Y., Heckbert S.R., and Aleksic N. Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. Am J Hematol 71 (2002) 285-290
18. Hillarp A., Zoller B., Svensson P.J., and Dahlback B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 78 (1997) 990-992
19. Margaglione M., Brancaccio V., Giuliani N., D'Andrea G., Cappucci G., Iannaccone L., et al. Increased risk for venous thrombosis in carriers of the prothrombin G→A20210 gene variant. Ann Intern Med 129 (1998) 89-93
20. Vicente V., Gonzalez-Conejero R., Rivera J., and Corral J. The prothrombin gene variant 20210A in venous and arterial thromboembolism. Haematologica 84 (1999) 356-362
21. Soria J.M., Almasy L., Souto J.C., Tirado I., Borell M., Mateo J., et al. Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 95 (2000) 2780-2785
22. Ho W.K., Hankey G.J., Quinlan D.J., and Eikelboom J.W. Risk of recurrent venous thromboembolism in patients with common thrombophilia: A systematic review. Arch Intern Med 166 (2006) 729-736
23. Eichinger S., Minar E., Hirschl M., Bialonczyk C., Stain M., Mannhalter C., et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 81 (1999) 14-17
24. Christiansen S.C., Cannegieter S.C., Koster T., Vandenbroucke J.P., and Rosendaal F.R. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293 (2005) 2352-2361
25. Ceelie H., Bertina R.M., van Hylckama Vlieg A., Rosendaal F.R., and Vos H.L. Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels. Thromb Haemost 85 (2001) 1066-1070
26. Gehring N.H., Frede U., Neu-Yilik G., Hundsdoerfer P., Vetter B., Hentze M.W., et al. Increased efficiency of mRNA 3′ end formation: A new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 28 (2001) 389-392
27. Carter A.M., Sachchithananthan M., Stasinopoulos S., Maurer F., and Medcalf R.L. Prothrombin G20210A is a bifunctional gene polymorphism. Thromb Haemost 87 (2002) 846-853
28. Ceelie H., Spaargaren-Van Riel C.C., Bertina R.M., and Vos H.L. G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3′-end formation. J Thromb Haemost 2 (2004) 119-127
29. Danckwardt S., Gehring N.H., Neu-Yilik G., Hundsdoerfer P., Pforsich M., Frede U., et al. The prothrombin 3′ end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. Blood 104 (2004) 428-435
30. von Ahsen N., and Oellerich M. The intronic prothrombin 19911A>G polymorphism influences splicing efficiency and modulates effects of the 20210G>A polymorphism on mRNA amount and expression in a stable reporter gene assay system. Blood 103 (2004) 586-593
31. Castaman G., Tosetto A., Simioni M., Ruggeri M., Madeo D., and Rodeghiero F. Phenotypic APC resistance in carriers of the A20210 prothrombin mutation is associated with an increased risk of venous thrombosis. Thromb Haemost 86 (2001) 804-808
32. Kyrle P.A., Mannhalter C., Beguin S., Stumpflen A., Hirschl M., Weltermann A., et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 18 (1998) 1287-1291
33. Curvers J., Thomassen M.C., Rimmer J., Hamulyak K., van der Meer J., Tans G., et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 88 (2002) 5-11
34. Koenen R.R., Tans G., van Oerle R., Hamulyak K., Rosing J., and Hackeng T.M. The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation. Blood 102 (2003) 1686-1692
35. Wolberg A.S., Monroe D.M., Roberts H.R., and Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: A possible mechanism of the increased thrombotic risk. Blood 101 (2003) 3008-3013
36. Orstavik K.H., Magnus P., Reisner H., Berg K., Graham J.B., and Nance W. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 37 (1985) 89-101
37. Koster T., Blann A.D., Briët E., Vandenbroucke J.P., and Rosendaal F.R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345 (1995) 152-155
38. Morelli V.M., De Visser M.C.H., Vos H.L., Bertina R.M., and Rosendaal F.R. ABO blood group genotypes and the risk of venous thrombosis: Effect of factor V Leiden. J Thromb Haemost 3 (2005) 183-185
39. Souto J.C., Almasy L., Borrell M., Blanco-Vaca F., Mateo J., Soria J.M., et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J Hum Genet 67 (2000) 1452-1459
40. Kraaijenhagen R.A., in't Anker P.S., Koopman M.M., Reitsma P.H., Prins M.H., van den Ende A., et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 83 (2000) 5-9
41. Lensen R., Bertina R.M., Vandenbroucke J.P., and Rosendaal F.R. High factor VIII levels contribute to the thrombotic risk in families with factor V Leiden. Br J Haematol 114 (2001) 380-386
42. Patel R.K., Ford E., Thumpston J., and Arya R. Risk factors for venous thrombosis in the black population. Thromb Haemost 90 (2003) 835-838
43. Oger E., Lacut K., Van Dreden P., Bressollette L., Abgrall J.F., Blouch M.T., et al. High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly. Haematologica 88 (2003) 465-469
44. Tirado I., Mateo J., Soria J.M., Oliver A., Martinez-Sanchez E., Vallve C., et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost 93 (2005) 468-474
45. Bank I., Libourel E.J., Middeldorp S., Hamulyak K., van Pampus E.C., Koopman M.M., et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 3 (2005) 79-84
46. Wells P.S., Langlois N.J., Webster M.A., Jaffey J., and Anderson J.A. Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada-Is it necessary to define a new upper reference range for factor VIII?. Thromb Haemost 93 (2005) 842-846
47. Kyrle P.A., Minar E., Hirschl M., Bialonczyk C., Stain M., Schneider B., et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343 (2000) 457-462
48. Legnani C., Mattarozzi S., Cini M., Cosmi B., Favaretto E., and Palareti G. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. Br J Haematol 134 (2006) 227-232
49. O'Donnell J., Mumford A.D., Manning R.A., and Laffan M. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 83 (2000) 10-13
50. Kamphuisen P.W., Houwing-Duistermaat J.J., van Houwelingen H.C., Eikenboom H.C.J., Bertina R.M., and Rosendaal F.R. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost 79 (1998) 323-327
51. Kamphuisen P.W., Lensen R., Houwing-Duistermaat J.J., Eikenboom H.C.J., Harvey M., Bertina R.M., et al. Heritability of elevated factor VIII antigen levels in factor V Leiden families with thrombophilia. Br J Haematol 109 (2000) 519-522
52. Schambeck C.M., Hinney K., Haubitz I., Mansouri T.B., Wahler D., and Keller F. Familial clustering of high factor VIII levels in patients with venous thromboembolism. Arterioscler Thromb Vasc Biol 21 (2001) 289-292
53. Mansvelt E.P., Laffan M., McVey J.H., and Tuddenham E.G. Analysis of the F8 gene in individuals with high plasma factor VIII: C levels and associated venous thrombosis. Thromb Haemost 80 (1998) 561-565
54. Kamphuisen P.W., Eikenboom H.C.J., Rosendaal F.R., Koster T., Blann A.D., Vos H.L., et al. High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 115 (2001) 156-158
55. De Visser M.C.H., Sandkuijl L.A., Lensen R.P., Vos H.L., Rosendaal F.R., and Bertina R.M. Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci. J Thromb Haemost 1 (2003) 1771-1776
56. Berger M., Mattheisen M., Kulle B., Schmidt H., Oldenburg J., Bickeboller H., et al. High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11. Blood 105 (2005) 638-644
57. Scanavini D., Legnani C., Lunghi B., Mingozzi F., Palareti G., and Bernardi F. The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels. Thromb Haemost 93 (2005) 453-456
58. Nossent A.Y., Eikenboom H.C.J., Vos H.L., Bakker E., Tanis B.C., Doggen C.J.M., et al. Haplotypes encoding the factor VIII 1241 Glu variation, factor VIII levels and the risk of venous thrombosis. Thromb Haemost 95 (2006) 942-948
59. Small M., Tweddel A.C., Rankin A.C., Lowe G.D., Prentice C.R., and Forbes C.D. Blood coagulation and platelet function following maximal exercise: Effects of beta-adrenoceptor blockade. Haemostasis 14 (1984) 262-268
60. O'Donnell J., Manning R.A., and Laffan M.A. Beta-adrenergic receptor polymorphisms in patients with elevated factor VIII levels with venous thrombosis. Br J Haematol 123 (2003) 139-141
61. Nossent A.Y., Dai L., Rosendaal F.R., Vos H.L., and Eikenboom H.C.J. Beta 2 adrenergic receptor polymorphisms: Association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis. J Thromb Haemost 3 (2005) 405-407
62. Saenko E.L., Yakhyaev A.V., Mikhailenko I., Strickland D.K., and Sarafanov A.G. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem 274 (1999) 37685-37692
63. Bovenschen N., Herz J., Grimbergen J.M., Lenting P.J., Havekes L.M., Mertens K., et al. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood 101 (2003) 3933-3939
64. Cunningham N., Laffan M.A., Manning R.A., and O'Donnell J.S. Low-density lipoprotein receptor-related protein polymorphisms in patients with elevated factor VIII coagulant activity and venous thrombosis. Blood Coagul Fibrinolysis 16 (2005) 465-468
65. Henkens C.M., Bom V.J., and van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 74 (1995) 1198-1199
66. De Visser M.C.H., van Hylckama Vlieg A., Tans G., Rosing J., Dahm A.E., Sandset P.M., et al. Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost 3 (2005) 1488-1494
67. O'Donnell J., Mumford A.D., Manning R.A., and Laffan M.A. Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol 115 (2001) 687-691
68. van Hylckama Vlieg A., van der Linden I.K., Bertina R.M., and Rosendaal F.R. High levels of factor IX increase the risk of venous thrombosis. Blood 95 (2000) 3678-3682
69. Lowe G., Woodward M., Vessey M., Rumley A., Gough P., and Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb Haemost 83 (2000) 530-535
70. Weltermann A., Eichinger S., Bialonczyk C., Minar E., Hirschl M., Quehenberger P., et al. The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost 1 (2003) 28-32
71. Sweeney J.D., and Hoernig L.A. Age-dependent effect on the level of factor IX. Am J Clin Pathol 99 (1993) 687-688
72. Khachidze M., Buil A., Viel K.R., Porter S., Warren D., Machiah D.K., et al. Genetic determinants of normal variation in coagulation factor (F) IX levels: genome-wide scan and examination of the FIX structural gene. J Thromb Haemost 4 (2006) 1537-1545
73. Gevers Leuven J.A., Kluft C., Bertina R.M., and Hessel L.W. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J Lab Clin Med 109 (1987) 631-636
74. Naito K., and Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 266 (1991) 7353-7358
75. Bouma B.N., and Griffin J.H. Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem 252 (1977) 6432-6437
76. Minnema M.C., Friederich P.W., Levi M., von dem Borne P.A., Mosnier L.O., Meijers J.C., et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 101 (1988) 10-14
77. Bouma B.N., and Meijers J.C. Role of blood coagulation factor XI in downregulation of fibrinolysis. Curr Opin Hematol 7 (2000) 266-272
78. Meijers J.C., Tekelenburg W.L., Bouma B.N., Bertina R.M., and Rosendaal F.R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 342 (2000) 696-701
79. Eichinger S., Schönauer V., Weltermann A., Minar E., Bialonczyk C., Hirschl M., et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 103 (2004) 3773-3776
80. Gerdes V.E., Kraaijenhagen R.A., Vogels E.W., ten Cate H., and Reitsma P.H. Factor XI gene analysis in thrombophilia and factor XI deficiency. J Thromb Haemost 2 (2004) 1015-1017
81. Bouma B.N., and Meijers J.C. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 1 (2003) 1566-1574
82. Nesheim M. Thrombin and fibrinolysis. Chest 124 suppl (2003) 33S-39S
83. van Tilburg N.H., Rosendaal F.R., and Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95 (2000) 2855-2859
84. Juhan-Vague I., Renucci J.F., Grimaux M., Morange P.E., Gouvernet J., Gourmelin Y., et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 20 (2000) 2156-2161
85. Henry M., Aubert H., Morange P.E., Nanni I., Alessi M.C., Tiret L., et al. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: Evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 97 (2001) 2053-2058
86. Tregouet D.A., Aubert H., Henry M., Morange P., Visvikis S., Juhan-Vague I., et al. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum Genet 109 (2001) 191-197
87. Brouwers G.J., Vos H.L., Leebeek F.W., Bulk S., Schneider M., Boffa M., et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 98 (2001) 1992-1993
88. Frere C., Tregouet D.A., Morange P.E., Saut N., Kouassi D., Juhan-Vague I., et al. Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. Blood 108 (2006) 1562-1568
89. Franco R.F., Fagundes M.G., Meijers J.C., Reitsma P.H., Lourenco D., Morelli V., et al. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 86 (2001) 510-517
90. Morange P.E., Aillaud M.F., Nicaud V., Henry M., and Juhan-Vague I. Ala147Thr and C+1542G polymorphisms in the TAFI gene are not asssociated with a higher risk of venous thrombosis in FV Leiden carriers. Thromb Haemost 86 (2001) 1583-1584
91. Zidane M., De Visser M.C.H., ten Wolde M., Vos H.L., de Monye W., Bertina R.M., et al. Frequency of the TAFI -438 G/A and factor XIIIA Val34Leu polymorphisms in patients with objectively proven pulmonary embolism. Thromb Haemost 90 (2003) 439-445
92. Zee R.Y., Hegener H.H., and Ridker P.M. Carboxypeptidase B2 gene polymorphisms and the risk of venous thromboembolism. J Thromb Haemost 3 (2005) 2819-2821
93. Martini C.H., Brandts A., de Bruijne E.L., van H.V., Leebeek F.W., Lisman T., et al. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 134 (2006) 92-94
94. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
95. Kamphuisen P.W., Rosendaal F.R., Eikenboom H.C.J., Bos R., and Bertina R.M. Factor V antigen levels and venous thrombosis: Risk profile, interaction with factor V Leiden, and relation with factor VIII antigen levels. Arterioscler Thromb Vasc Biol 20 (2000) 1382-1386
96. De Visser M.C.H., Poort S.R., Vos H.L., Rosendaal F.R., and Bertina R.M. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost 85 (2001) 1011-1017
97. von Kanel R., Wuillemin W.A., Furlan M., and Lammle B. Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagul Fibrinolysis 3 (1992) 555-561
98. Koster T., Rosendaal F.R., Briët E., and Vandenbroucke J.P. John Hageman's factor and deep-vein thrombosis: Leiden Thrombophilia Study. Br J Haematol 87 (1994) 422-424
99. Lavigne G., Mercier E., Quere I., Dauzat M., and Gris J.C. Thrombophilic families with inheritably associated high levels of coagulation factors VIII, IX and XI. J Thromb Haemost 1 (2003) 2134-2139